Capital Market Intelligence
Act On The Funding Signal Before The Market Sees The Trial. BioAlliance Detects The Close. You Start The Conversation Before The RFP Exists.
Timing is everything in life science capital markets. A funding close is a leading indicator. Within a defined window, that company is likely to initiate a clinical trial, issue an RFP, or begin evaluating CRO, CDMO, SMO, and site network partners. By the time a trial is announced publicly, the early conversations have already happened. The preferred vendors are already in conversations. The window has already moved.
Funding Signal monitors the capital markets for companies that have just secured funding and translates each close into a prioritized commercial trigger. Customized to your geography, therapeutic focus, company size, development stage, financing type, and target investor categories. Market intelligence filtered to the capital conditions relevant to your specific commercial objectives.
The Commercial Edge Of Knowing Before The Market Does.
The Funding Readiness Index.
The Funding Readiness Index is modeled quarterly across venture, strategic, and public market signals. It integrates investor activity patterns, sector allocation data, comparable transaction timing, and structural market conditions into a single composite readiness indicator. Organizations that time their financing approach to a Funding Readiness Index above threshold close at a materially higher rate than those who approach the market on internal timelines alone.
What The Index Covers
Investor behavior patterns and sector sentiment tracked continuously. Structural indicators separating organizations that close from those that stall in diligence. Covers venture, strategic, and public market signals simultaneously.
What Funding Signal Monitors.
Funding Close Detection
Seed, Series A, Series B, and beyond. Detected at close, not at press release. The signal fires at the moment the capital event is confirmed.
Investor Behavior Patterns
Which investors are active in your target therapeutic space, which sector allocations are accelerating, and which signals indicate a window is opening or closing.
Sector Sentiment Shifts
Market conditions that indicate whether the capital environment supports or constrains clinical development activity in your target areas.
Development Stage Implications
Every funding close is interpreted against the development stage of the lead asset to determine the commercial trigger window, when that company is most likely to begin evaluating service partners.
Geographic Scope
Target specific capital markets, regulatory jurisdictions, and investor geographies.
Therapeutic Focus
Filter by therapeutic area and development stage to see only the funding activity in the markets relevant to your BD priorities.
Financing Type
Seed, Series A, Series B, strategic investment, public offering, or custom stage configuration.
Target Investor Categories
Venture capital, strategic investors, crossover funds, or public market participants. Configure to match where your ICP companies are getting funded.
You Now Know What
The Revenue Infrastructure Diagnostic tells you what to build first so you can use it.
Intelligence You Have
Your CMR Score identifies the structural gaps that determine whether Signal Suite intelligence converts into pipeline or sits unused in a PDF.
The Picture
How The Signal Behaves.
Commission
Configure Funding Signal To Your Market.
Every edition is filtered to your geography, therapeutic focus, company size, and BD priorities before a single entry is researched.